Alison Whitman, MD
Family Medicine · Abingdon, VANPI 1669418067
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 1,026 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,026 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$2K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- AstraZeneca$894
- Johnson & Johnson$890
- plus $8K from 47 others
What the payments were for
- Speaking & faculty fees$450%
- Food & beverage$16,75199%
- Education$1591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,955 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 269 | $343,196 |
| EliquisApixaban | 302 | $285,045 |
| JardianceEmpagliflozin | 142 | $123,715 |
| MounjaroTirzepatide | 87 | $99,797 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $99,432 |
| XareltoRivaroxaban | 88 | $81,020 |
| LinzessLinaclotide | 65 | $49,871 |
| FarxigaDapagliflozin Propanediol | 42 | $47,077 |
| RybelsusSemaglutide | 21 | $32,584 |
| JanuviaSitagliptin Phosphate | 18 | $28,538 |
| MyrbetriqMirabegron | 49 | $27,461 |
| Repatha SureclickEvolocumab | 21 | $22,862 |
| TrintellixVortioxetine Hydrobromide | 22 | $20,487 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $19,172 |
| EntrestoSacubitril/Valsartan | 12 | $18,229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,441 | $375,781290 claims |
| PfizerEliquis, Premarin | $733 | $297,451325 claims |
| Boehringer IngelheimJardiance | $303 | $123,715142 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $567 | $113,666169 claims |
| Lilly USA, LLCMounjaro | $1,480 | $99,79787 claims |
| Johnson & JohnsonXarelto, Invokana | $890 | $90,942101 claims |
| AbbVieLinzess, Vraylar, Synthroid | $2,373 | $77,566207 claims |
| AstraZenecaFarxiga | $894 | $47,07742 claims |
| MerckJanuvia | $51 | $28,53818 claims |
| Astellas Pharma US IncMyrbetriq | $358 | $27,46149 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $624 | $20,48722 claims |
| NovartisEntresto | $538 | $18,22912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Abingdon
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
- John ClayColonial Heights$40K
- Thomas RobesonNewport News$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.